Latest Licensing Agreements News

Vection Technologies has secured a $2.6 million contract to co-develop SAFE-XR, an AI-powered safety compliance platform using augmented reality and wearable tech for industrial inspections in Italy.

X2M Connect has secured a $3 million deal to supply 100,000 IoT-connected personal safety devices for Seoul’s 2025 Smart City initiative, with potential to scale to one million units.

X2M Connect Limited has secured $1.95 million through a share placement and convertible note conversion, aiming to strengthen its balance sheet and accelerate growth in AI and IoT sectors.

Hazer Group Limited has opened a $2 million underwritten Share Purchase Plan, offering eligible shareholders in Australia and New Zealand the chance to buy shares at the same price as a recent institutional placement. The funds will support the commercialisation of its methane reactor technology and synthetic graphite development.

HeraMED has partnered with RMIT University and the Digital Health CRC to develop AI-driven maternity care models focused on culturally diverse populations, aiming to improve pre-term delivery risk prediction and personalised care.

Hazer Group unveils a strategic alliance with engineering giant KBR to fast-track its low-cost clean hydrogen technology, targeting major global markets with a capex-lite licensing model.

Hazer Group has raised A$8 million through a share placement and launched a A$2 million Share Purchase Plan to accelerate its clean hydrogen and graphite technology commercialisation.

Anagenics Limited’s proprietary hair regrowth technology powers the newly launched Bouf Haircare brand, which has achieved over $500,000 in sales in its first week, setting the stage for a lucrative royalty stream.

Streamplay’s subsidiary Noodlecake has inked a three-year licensing agreement with Amazon to adapt and distribute one of its owned games on Amazon’s gaming platform, marking a strategic expansion into a new marketplace.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

Insurance Australia Group (IAG) has entered a strategic alliance with The Royal Automobile Club of Western Australia (RAC), acquiring RAC Insurance and securing a 20-year exclusive distribution agreement. This move significantly boosts IAG's presence in Western Australia and is expected to enhance earnings and operational synergies.